Abstract
Two molecular weight variants of the interferon (IFN)-induced intracellular enzyme 2′,5′-oligoadenylate (2-5A) synthetase have been described recently; a 100-kD (cytoplasmic) and a 30-kD (intranuclear) form of the enzyme. The 30-kD form has been located primarily in the nucleus, while the 100-kD enzyme was found mainly in the cytoplasm. We examined 2-5A synthetase activity in extracts of human melanoma (Hs294t) cells treated with either recombinant (r) IFN-αA or rIFN-γ to determine the differential regulation of these enzyme subtypes by treatment with the two types of IFN. Cells were treated (continuous exposure) with doses of rIFN-αA (1,000 U/ml) or rIFN-γ (5,000 U/ml), each of which reduced the number of viable cells to 50% of control values (ED50) by day 3 of treatment. At equieffective doses, the maximal increase in 2-5A synthetase occurred at 48 h for both rIFN-αA and rIFN-γ continuous exposure. The maximal 2-5A intracellular activities at 48 h were 800 ± 40 and 160 ± 15 nmoles/mg protein for rIFN-αA and rIFN-γ treatment, respectively. High-performance gel permeation chromatography of cell lysates resolved the 2-5A activity into both 100-kD and 30-kD fractions. At 48 h after treatment with rIFN-αA, the activity of the 30-kD synthetase was approximately twofold greater than that of the 100-kD enzyme. In contrast, the activity of both 30- and 100-kD enzymes were equivalent 48 h after treatment with rIFN-γ. The 100-kD enzyme activity did not vary substantially in the first 24 h after exposure to IFN-γ. However, the change in total 2-5A synthetase activity 24 h after IFN-γ treatment appeared to be due primarily to changes in the 30-kD enzyme. These studies show that the activities of the two molecular weight species of 2-5A synthetase which may exist in different subcellular locations are regulated differently at various times after exposure to IFNs. In addition, the importance of intracellular 2-5A activity to the antiproliferative activity of the IFNs may depend upon the location and activity of the various enzymatic forms within the cell.
Get full access to this article
View all access options for this article.
